TR200102262T2 - Method for preventing or reducing cardiovascular events related to coronary intervention. - Google Patents

Method for preventing or reducing cardiovascular events related to coronary intervention.

Info

Publication number
TR200102262T2
TR200102262T2 TR2001/02262T TR200102262T TR200102262T2 TR 200102262 T2 TR200102262 T2 TR 200102262T2 TR 2001/02262 T TR2001/02262 T TR 2001/02262T TR 200102262 T TR200102262 T TR 200102262T TR 200102262 T2 TR200102262 T2 TR 200102262T2
Authority
TR
Turkey
Prior art keywords
cardiovascular events
preventing
coronary intervention
events related
reducing cardiovascular
Prior art date
Application number
TR2001/02262T
Other languages
Turkish (tr)
Inventor
R. Granett Jeffrey
H. Shusterman Neil
C. U'prichard David
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR200102262T2 publication Critical patent/TR200102262T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bir memelide özellikle bie insanda koroner müdahale ile ilgili kardiyovasküler olaylarin önlenmesi veya azaltilmasi için, koroner müdahale ile ilgili olarak 300 mg 1100 mg günlük dozda N'(3',4'-dimethoksisinnamoil)anthranilic asid (N-5') veya farmasötik olarak kabul edilir tuzunun verilmesini içeren bir yöntemN '(3', 4'-dimethoxysinnamoil) anthranilic acid (N-5 ') or pharmaceutically acceptable in a mammal, especially in a human, at a daily dose of 300 mg 1100 mg in relation to coronary intervention to prevent or reduce cardiovascular events a method that involves the administration of the saline salt

TR2001/02262T 1999-02-03 2000-02-02 Method for preventing or reducing cardiovascular events related to coronary intervention. TR200102262T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11846399P 1999-02-03 1999-02-03

Publications (1)

Publication Number Publication Date
TR200102262T2 true TR200102262T2 (en) 2002-02-21

Family

ID=22378760

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02262T TR200102262T2 (en) 1999-02-03 2000-02-02 Method for preventing or reducing cardiovascular events related to coronary intervention.

Country Status (17)

Country Link
EP (1) EP1180027A4 (en)
JP (1) JP2002536326A (en)
KR (1) KR20010101933A (en)
CN (1) CN1338930A (en)
AR (1) AR022475A1 (en)
AU (1) AU2978500A (en)
BR (1) BR0007901A (en)
CA (1) CA2361578A1 (en)
CO (1) CO5160246A1 (en)
HU (1) HUP0200148A3 (en)
IL (1) IL144719A0 (en)
MX (1) MXPA01007833A (en)
NO (1) NO20013789L (en)
PL (1) PL349926A1 (en)
TR (1) TR200102262T2 (en)
WO (1) WO2000045810A1 (en)
ZA (1) ZA200106297B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (en) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 Preventive and therapeutic agent for intimal cell hyperproliferative disease
EP0855387A4 (en) * 1995-09-07 1999-09-15 Kissei Pharmaceutical 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
JP2002536326A (en) 2002-10-29
ZA200106297B (en) 2002-07-31
EP1180027A1 (en) 2002-02-20
HUP0200148A2 (en) 2002-05-29
PL349926A1 (en) 2002-10-21
HUP0200148A3 (en) 2003-06-30
EP1180027A4 (en) 2004-11-17
CN1338930A (en) 2002-03-06
AR022475A1 (en) 2002-09-04
IL144719A0 (en) 2002-06-30
BR0007901A (en) 2001-10-30
MXPA01007833A (en) 2002-06-21
AU2978500A (en) 2000-08-25
WO2000045810A1 (en) 2000-08-10
CA2361578A1 (en) 2000-08-10
CO5160246A1 (en) 2002-05-30
NO20013789D0 (en) 2001-08-02
KR20010101933A (en) 2001-11-15
NO20013789L (en) 2001-09-28

Similar Documents

Publication Publication Date Title
RO116342B1 (en) Oral liquid pharmaceutical composition
EG25822A (en) Quinolinyl-pyrrolopyrazoles
NZ514574A (en) Novel method of treatment
ATE237330T1 (en) ADMINISTRATION OF NICOTINE IN THE COLON FOR THE TREATMENT OF INFLAMMATORY VITAL DISEASE
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
DE69738667D1 (en) PREVENTATION AND TREATMENT OF COLONADOMENO OR COLONMICROADENOMA WITH 6-FLUORO-SODEOXYCHOLIC ACID
RS54050B1 (en) Formulations and methods for treating amyloidosis
DK0998287T3 (en) Use of levobupivacaine
PT1039900E (en) THERAPEUTIC AGENTS
ATE311928T1 (en) (-)-PSEUDOEPHEDRINE AS A SYMPATHOMIMETIC DRUG
EE200100066A (en) Use of Sodium Chloride to Reduce Gastrointestinal Side Effects Due to Administration of Camptothecin Derivatives
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
TR200102262T2 (en) Method for preventing or reducing cardiovascular events related to coronary intervention.
PT1058544E (en) INHIBITION OF TNF ACTIVITY
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
TR200102245T2 (en) Method for preventing or reducing cardiovascular events related to coronary intervention.
JP2002500181A5 (en)
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
DK0711163T3 (en) Use of benzydamine in the treatment of pathological conditions caused by TNF
EP1347754A4 (en) Compositions for adhesion prevention
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
YU28700A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
RU2000119692A (en) METHOD FOR TREATING PSORIASIS
ECSP982512A (en) TRANSPARENT INJECTABLE FORMULATION OF ANESTHETIC COMPOUND
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions